Mr. Quang Pham

Chairman and CEO


Mr. Pham is a biopharmaceutical entrepreneur with over 20 years of experience in founding, financing, and growing companies. Prior to founding Espero, he started Lathian Systems, an innovative company that provided online data and marketing services to pharmaceutical and biotech companies.

As Chairman and CEO, he raised venture capital funding for Lathian, developed products, grew revenues, and led its eventual sale to D&R Communications. Additionally, Mr. Pham was President and CEO of Monarch Staffing, a healthcare staffing company in California, and Vice President and General Manager with QTC Management, the largest private provider of government-outsourced disability examinations. Following service as a U.S. Marine Corps aviator, he began his business career in sales roles with Astra-Merck and Genentech. He is a published author and holds a B.A. in Economics from UCLA. Mr. Pham has also received the BioFlorida’s Entrepreneur of the Year Award, named a Veteran of Influence by the Jacksonville Business Journal (JBJ) and recognized as a finalist for the Ernst & Young Entrepreneur Of The Year® 2017 Award. In July, the JBJ named Espero as the fastest growing private company in Northeast Florida. He currently serves on the Board of BioFlorida and is a past director of InHouseUSA, Inc., the Marine Corps Scholarship Foundation and the Chapman University Argyros School Board of Advisors.

Mr. Jeff Cole

President and CFO


Mr. Cole has over 23 years of experience in finance, business development and commercial operations at public and privately held companies. This includes more than 15 years in the pharmaceutical industry holding various senior executive roles at companies such as Valeant Pharmaceuticals (NYSE: VRX), Solco Healthcare US, MarcasUSA, and Legacy Pharmaceuticals. His positions at Valeant included CFO North America, VP of Corporate Development, and General Manager of the US Specialty Division.

During his tenure, Valeant’s revenue in North America increased more than 300%, and while General Manager, Mr. Cole managed a US commercial portfolio of prescription and OTC products across multiple therapeutic areas. As President of Solco Healthcare US, Mr. Cole launched and managed this US commercial pharmaceutical subsidiary of Legacy Pharmaceuticals while serving as the company’s international CFO. Prior to Espero, Mr. Cole founded J. Scott Capital, a firm that provides capital resources to early stage pharmaceutical companies. He also spent six years at PwC Consulting, and served as a principal in the financial management consulting practice. Mr. Cole is a CPA and received his MBA with honors from the University of Michigan. He holds a BS in Accounting from the University of Southern California.

Mr. Wayne Yetter

Director and Senior Advisor


Mr. Yetter is a pharmaceutical industry veteran, board director and advisor. He has held leadership positions at global companies, including President and CEO of Novartis Pharmaceuticals and founding CEO of Astra-Merck (now AstraZeneca). He has also held senior roles at IMS Health, Odyssey Pharmaceuticals, and Verispan.

Mr. Yetter serves as a director of InfuSystem Holdings, with previous board roles that include Chairman of NuPathe, Noven Pharmaceuticals, Transkaryotic Therapies and Lead Independent Director of Matria Healthcare. He was previously a member of the pharmaceutical industry association (PhRMA) Executive Committee. Mr. Yetter holds a B.A. in Biology from Wilkes University and an M.B.A from Bryant University.

Mr. Stefan Roever


Mr. Roever has a broad entrepreneurial, software, and finance background. He is CEO and founder of Genia Technologies, a next generation DNA sequencing company based in Mountain View, CA. Genia was sold to Roche in June 2014 for $350 million. He’s also founder and Chairman of gBox, a video monetization and distribution platform.

He is an active private equity investor and currently serves on the board of WRS Materials, a roll-up of wafer reclaim companies. He was also Co-Founder and CEO of Brokat Technologies, an encryption banking software company. Brokat reached a several billion dollar market cap and went public in 1998 on the Frankfurt Stock Exchange and on NASDAQ in 2000. Mr. Roevner was honored with the Ernst and Young Entrepreneur of the Year Award in Germany. He is a two time award holder of Technology Pioneer by the World Economic Forum. He earned degrees in both economics and law from the University of Tübingen. He holds several patents on digital rights management and has published several scientific papers on DNA sequencing.

Dr. Larry Hsu, Ph.D.


Dr. Hsu is currently Chairman & CEO of Lifemax Healthcare International Corporation and general partner at Hercules BioVenture Partners as well as Capital TEN II Fund. He co-founded Impax Pharmaceuticals, Inc., a drug-delivery technology-based pharmaceutical company with headquarters located in the San Francisco Bay Area.

In 1999, Impax went public through a reverse acquisition of Global Pharmaceuticals and changed its name to Impax Laboratories, Inc. Dr. Hsu was the President of Impax Laboratories until October 2006 when he assumed additional responsibility of Chief Executive Officer.He worked at Abbott laboratories for 15 years. During the last four years at Abbott, he was the Director of Product Development in charge of worldwide product development, process engineering, clinical supplies manufacturing and production technical support of all dosage forms. He received his Ph.D. degree in Pharmaceutics from University of Michigan and his B.S. degree in Pharmacy from National Taiwan University.

Mr. Henrik Hesse


Currently Mr. Hesse serves as Executive Director at Pohl-Boskamp, managing Legal, Finance, and R&D. He also acts as an honorary judge for labor law with the court system in Germany. He started his career as an attorney with a law firm, prior to joining Pohl-Boskamp as General Counsel.

Throughout his 15 year tenure with Pohl-Boskamp, Mr. Hesse has held several positions, as well as its affiliated companies. His experience in the pharmaceutical industry include International Sales, Secretary, and Managing Director.

Dr. Peter G. Milner
MD, FACC


Dr. Milner was a co-founder and Executive Chairman of Armetheon, Inc. He has been CEO of Heart Metabolics Limited UK (now HMBL) since 2011 and was also CEO of Heart Metabolics Limited Ireland from 2014 to 2015.

In 2007, Dr. Milner co-founded Optivia Biotechnology, a private company now recognized as a leader in the emerging field of transporter biology. He is also a co-founder and President & CEO of AshHill Pharmaceutical Investments, LLC. In 1997, Dr. Milner co-founded ARYx Therapeutics (NASDAQ:ARYX), where he served as CEO until 2005, and President from 2005 to 2010 with overall responsibility for R&D. In 1990, he co-founded CV Therapeutics (NASDAQ:CVTX), where as a member of senior management from 1992-1996, he in-licensed and co-invented several successful pharmaceuticals. CV Therapeutics was acquired by Gilead for $1.5B in cash in 2009.

In 2005, Dr. Milner was instrumental in restructuring his family pharmaceutical company ML Laboratories (MLB.LSE) and its subsequent merger to form Vectura (VEC.LSE), a profitable company and one of the world’s leading makers of inhaled products.

Prior to 1992, Dr. Milner was an assistant professor of medicine at Washington University in St. Louis. His research led to the discovery of pleiotrophin (PTN), a novel growth factor that regulates stem cell differentiation, organ development, and the epithelial mesenchymal transition (EMT). He was educated at the University of Liverpool, receiving his medical degree in 1980, before completing his postgraduate training at Johns Hopkins Hospital, The University of Virginia, and Washington University in St. Louis.

He is a Fellow of the American College of Cardiology (FACC), and a board-certified physician and cardiologist. He serves as adjunct clinical faculty at Stanford University School of Medicine and as a board member of the California Healthcare Institute (CHI).